Page 25 - FLIPBOOK
P. 25
Post-hoc analysis of CV safety with GnRH agonists and
degarelix.
Duration
Study Comparator Publication
(months) 2328
CS21 Klotz et al. Patients
Pivotal phase III, 12 Leuprolide BJU Int 2008
monthly dose
CS35 Shore et al.
3-month depot 12 Goserelin SUO 2012 1491 837
formulation degarelix GnRH agonist
CS37 7–12 Crawford et al.
Intermittent dosing Leuprolide SUO 2013
CS28 3 Goserelin* Anderson et al. 458 379
LUTS relief Urol Int 2012 Goserelin Leuprolide
CS30
Neoadjuvant to 3 Goserelin* Mason et al.
Clin Oncol 2013
radical RT
CVD
CS31 3 Goserelin* Axcrona et al. 463 (31%) history 245 (29%)
TPV reduction BJU Int 2012
CVD history was defined as an event of myocardial ischemia, coronary artery disease, myocardial infarction, cerebrovascular accident,
angina pectoris or coronary artery bypass at baseline
1. Albertsen PC et al. Eur Urol 2014;65:565-73.
